Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase I for Dravet Syndrome (Severe Myoclonic Epilepsy...